Literature DB >> 30105172

Progressive multifocal leukoencephalopathy with extended natalizumab dosing.

Laura E Baldassari1, Stephen E Jones1, David B Clifford1, Robert J Fox1.   

Abstract

Entities:  

Year:  2018        PMID： 30105172      PMCID： PMC6075974          DOI： 10.1212/CPJ.0000000000000457

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  6 in total

1.  Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Authors:  J Kuhle; R Gosert; R Bühler; T Derfuss; R Sutter; O Yaldizli; E-W Radue; C Ryschkewitsch; E O Major; L Kappos; S Frank; H H Hirsch
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

2.  Extended interval dosing of natalizumab in multiple sclerosis.

Authors:  L Zhovtis Ryerson; T C Frohman; J Foley; I Kister; B Weinstock-Guttman; C Tornatore; K Pandey; S Donnelly; S Pawate; R Bomprezzi; D Smith; C Kolb; S Qureshi; D Okuda; J Kalina; Z Rimler; R Green; N Monson; T Hoyt; M Bradshaw; J Fallon; E Chamot; M Bucello; S Beh; G Cutter; E Major; J Herbert; E M Frohman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-02-25       Impact factor: 10.154

Review 3.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

4.  Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.

Authors:  José Vicente Hervás; Silvia Presas-Rodríguez; Ane Miren Crespo-Cuevas; Tamara Canento; Manuel Lozano-Sánchez; Anna Massuet-Vilamajó; Cristina Ramo-Tello
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

5.  Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants.

Authors:  Caroline F Ryschkewitsch; Peter N Jensen; Eugene O Major
Journal:  J Clin Virol       Date:  2013-04-23       Impact factor: 3.168

6.  7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study.

Authors:  Tim Sinnecker; Jalal Othman; Marc Kühl; Ralf Mekle; Inga Selbig; Thoralf Niendorf; Annett Kunkel; Peter Wienecke; Peter Kern; Friedemann Paul; Juergen Faiss; Jens Wuerfel
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-10-29
  6 in total
  2 in total

1.  Four cases of natalizumab-related PML: a less severe course in extended interval dosing?

Authors:  Cristina Scarpazza; Nicola De Rossi; Giulietta Tabiadon; Maria Vittoria Turrini; Simonetta Gerevini; Ruggero Capra
Journal:  Neurol Sci       Date:  2019-06-07       Impact factor: 3.307

2.  No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).

Authors:  Helmut Butzkueven; Ludwig Kappos; Tim Spelman; Maria Trojano; Heinz Wiendl; Ray Su; Shirley Liao; Robert Hyde; Stephanie Licata; Pei-Ran Ho; Nolan Campbell
Journal:  Ther Adv Neurol Disord       Date:  2021-09-27       Impact factor: 6.570
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.